MTOR and hypertrophic cardiomyopathy: For example, NSML-associated PTPN11 mutants promote PI3K/AKT/mTOR hyperactivation and a mTOR inhibitor (sirolimus) improved NSML-associated hypertrophic cardiomyopathy in animal models and patients [51–54].